Table 1. Baseline characteristics.
| Characteristic | CLR group (n = 300) |
NCR group (n = 375) |
P-value |
| Data are presented as n (%), mean ± SD or median (interquartile range). ALT: alanine aminotransferase; Apo AI: apolipoprotein AI; Apo B: apolipoprotein B; AST: aspartate amino transferase; APTT: activated partial thromboplastin time; BMI: body mass index; CK: creatine kinase; CKMB: creatine kinase isoenzyme; DBIL: direct bilirubin; FIB: fibrinogen; GGT: gamma-glutamyl transpeptidase; HbA1c: glycated hemoglobin; HCY: homocysteine; HDL: high-density lipoprotein; LDL: Low-density lipoprotein; PLT: platelet count; PT: prothrombin time; SIB: indirect bilirubin; TG: triglyceride; TC: total cholesterol; TT: thrombin time; UA: uric acid. | |||
| Baseline characteristics | |||
| Age, yrs | 63.65 ± 11.72 | 62.47 ± 12.04 | 0.203 |
| Nationality (Han) | 280 (93.3%) | 366 (97.9%) | 0.003 |
| Sex (male) | 194 (64.7%) | 292 (77.9%) | 0.000 |
| BMI, kg/m2 | 25.06 (23.03, 27.34) | 25.34 (22.93, 27.68) | 0.430 |
| Past Medical History | |||
| Diabetes mellitus | 126 (42.0%) | 143 (38.1%) | 0.308 |
| Hypercholesterolemia | 75 (25.0%) | 68 (18.1%) | 0.030 |
| Hypertension | 198 (66.0%) | 247 (65.9%) | 0.971 |
| Smoking history | 150 (50.0%) | 225 (60.0%) | 0.009 |
| Drinking history | 97 (32.3%) | 154 (41.1%) | 0.020 |
| The number of vascular lesions ≥ 2 | 85 (28.3%) | 101 (26.9%) | 0.686 |
| Killip class 3–4 | 80 (26.7%) | 137 (36.5%) | 0.006 |
| Laboratory results | |||
| PLT, *109/L | 213.33 ± 61.76 | 228.92 ± 76.97 | 0.005 |
| APTT, s | 38.32 ± 7.66 | 38.47 ± 10.86 | 0.840 |
| PT(s) | 13.41 ± 0.98 | 13.48 ± 1.38 | 0.392 |
| FIB, g/L | 3.61 (3.14, 4.33) | 3.46 (3.02, 4.26) | 0.395 |
| TT, s | 16.82 ± 3.34 | 16.63 ± 2.24 | 0.385 |
| DBIL, μmol/L | 4.10 (3.16, 5.61) | 4.51 (3.23, 5.95) | 0.050 |
| SIB, μmol/L | 9.20 ± 5.26 | 9.91 ± 4.85 | 0.075 |
| UA, μmol/L | 343 ± 89.25 | 347 ± 87.30 | 0.591 |
| Urea, μmol/L | 5.91 ± 2.66 | 6.28 ± 2.98 | 0.102 |
| HCY, μmol/L | 17.03 ± 9.70 | 17.50 ± 10.29 | 0.564 |
| HDL-C, mmol/L | 1.05 ± 0.30 | 1.07 ± 0.31 | 0.321 |
| LDL-C, mmol/L | 2.53 ± 0.88 | 2.56 ± 0.91 | 0.756 |
| ApoAI, g/L | 1.13 ± 0.22 | 1.14 ± 0.24 | 0.810 |
| ApoB, g/L | 0.88 ± 0.39 | 0.91 ± 0.48 | 0.436 |
| TG, mmol/L | 1.71 (1.20, 2.27) | 1.51 (1.11, 2.17) | 0.046 |
| TC, mmol/L | 4.09 ± 1.03 | 4.15 ± 2.35 | 0.709 |
| HbA1c | 6.70% ± 1.58% | 6.78% ± 2.57% | 0.675 |
| Creatinine, μmol/L | 77.94 ± 44.60 | 79.95 ± 38.38 | 0.536 |
| GGT, IU/L | 36.75 ± 33.28 | 34.78 ± 29.14 | 0.421 |
| AST, IU/L | 32.00 (23.00, 69.00) | 46.50 (25.00, 110.50) | 0.000 |
| ALT, IU/L | 30.57 ± 31.89 | 34.64 ± 36.49 | 0.135 |
| CKMB, IU/L | 17.00 (11.00, 44.00) | 28.00 (17.75, 89.25) | 0.000 |
| CK, IU/L | 143.00 (71.00, 461.00) | 285.00 (103.75, 883.25) | 0.000 |
| CYP2C19 gene | 300 (44.4%) | 375 (55.6%) | 0.001 |
| Normal metabolizer | 109 (36.3%) | 186 (49.6%) | < 0.05 |
| Intermediate metabolizer | 148 (49.3%) | 160 (42.7%) | > 0.05 |
| Poor metabolizer | 43 (14.3%) | 29 (7.7%) | < 0.05 |